Fda approve medical in last year

Here are the stocks that have been approved by the FDA for medical indications in the past year:

FDA Approval Date in the past year
|code|stock code|stock name|Last Price|Last Change|Drug Name|Indication|FDA Approval Status|FDA Review Date|market_code|
|---|---|---|---|---|---|---|---|---|---|
|MESO|MESO.O|Mesoblast|12.29|8.28|RYONCIL(Remestemcel-L)|Acute graft-versus host disease|Approved|20241218|185|
|URGN|URGN.O|UroGen Pharma|15.2|6.14|UGN-102 (mitomycin)|Bladder cancer, Cancer|Pending|20250521|185|
|CTXR|CTXR.O|Citius|1.58|6.04|LYMPHIR (Denileukin Diftitox-cxdl, E7777)|T-cell lymphoma|Approved|20240808|186|
|APLT|APLT.O|Applied Therapeutics|0.46|5.78|Govorestat (AT-007)|Galactosemia, Rare genetic disease, Rare diseases|Pending|20241009|186|
|APLT|APLT.O|Applied Therapeutics|0.46|5.78|Govorestat (AT-007)|Galactosemia, Rare genetic disease, Rare diseases|Complete Response Letter|20241127|186|
|ABEO|ABEO.O|Abeona Therapeutics|6.57|4.95|Pz-cel (prademagene zamikeracel) EB-101 (COL7A1)|Recessive dystrophic epidermolysis bullosa|Approved|20250429|186|
|LXRX|LXRX.O|Lexicon Pharmaceuticals|1.35|4.66|ZYNQUISTA(sotagliflozin)|Type 1 diabetes, Diabetes|Pending|20241220|186|
|LXRX|LXRX.O|Lexicon Pharmaceuticals|1.35|4.66|ZYNQUISTA(sotagliflozin)|Type 1 diabetes, Diabetes|Pending|20241031|186|
|SCPH|SCPH.O|Scpharmaceuticals|4.72|4.19|FUROSCIX (furosemide)|Chronic kidney disease, Kidney disease|Approved|20250306|186|
|SCPH|SCPH.O|Scpharmaceuticals|4.72|4.19|FUROSCIX (furosemide)|Heart failure|Approved|20240812|186|

These stocks have undergone FDA approval for various medical indications over the past year. FDA approval is a significant milestone for these companies, as it allows them to bring their treatments to the market and potentially generate revenue. Investors may see these stocks as having increased potential for growth and profitability. However, it's important to note that FDA approval does not guarantee commercial success or profitability.